Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With Insomnia

Exclusion Criteria

• •The sleep disturbance must not be attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication.
• •Subject, if female of childbearing potential, which are unwilling to abstain from sexual intercourse or practice a double contraception method for the length of the study.
• •Mental retardation.
• •The presence of any untreated or uncompensated clinically significant renal, endocrine, hepatic, respiratory, cardiovascular, neurologic (excluding ADHD), hematologic, immunologic, cerebrovascular disease, or malignancy.
• •Subjects with a history of any significant gastrointestinal disease.
• •Presence of drug or alcohol abuse within one year before inclusion.
• •Current history of substance abuse/dependence.
• •Pregnant or breast-feeding.
• •Use of any hypnotics/psychotropics, antihistamines, melatonin, herbal products, or other sleep aids including clonidine for initiation or maintenance of sleep within one week or five half lives (whichever is longer), prior to screening and unwillingness to discontinue them at the screening visit.
• •Subject tested positive at screening or at baseline or at Day 1, on urine drug screen for drugs known to alter sleep (amphetamine/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates and alcohol).
• •Inability to swallow a pill in similar size as the tablets to be administered for this study.
• •Current or recent (\<60 days) participation in another clinical trial receiving an investigational drug.
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.